Marketing-authorisation holder · Germany
Mip Pharma Gmbh
14 medicines in 3 countries, as authorisation holder, manufacturer and marketer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Germany
14 medicines in 3 countries, as authorisation holder, manufacturer and marketer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
14 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CEFEPIMA MIP 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1000 mg · Polvo para solución inyectable y para perfusión | Cefepime | Spain | Authorised | 2015 |
| CEFEPIMA MIP 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2000 mg · Polvo para solución inyectable y para perfusión | Cefepime | Spain | Authorised | 2015 |
| Cefepime-MIP 1 g, poeder voor oplossing voor injectie of infusiePoeder voor oplossing voor injectie of infusie | Cefepime | Netherlands | Authorised | 2015 |
| Cefepime-MIP 2 g, Poeder voor oplossing voor injectie of infusiePoeder voor oplossing voor injectie of infusie | Cefepime | Netherlands | Authorised | 2015 |
| Ceftazidim MIP 1 g, poeder voor oplossing voor injectie of infusiePoeder voor oplossing voor injectie of infusie | Ceftazidime | Netherlands | Authorised | 2015 |
| Ceftazidim MIP 2 g, poeder voor oplossing voor injectie of infusiePoeder voor oplossing voor injectie of infusie | Ceftazidime | Netherlands | Authorised | 2015 |
| CEFTAZIDIMA MIP 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1164,81 mg · Polvo para solución inyectable y para perfusión | Ceftazidime | Spain | Authorised | 2018 |
| CEFTAZIDIMA MIP 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2329,62 mg · Polvo para solución inyectable y para perfusión | Ceftazidime | Spain | Authorised | 2018 |
| VANCOMICINA MIP 1000 MG POLVO PARA SOLUCION PARA PERFUSION EFG1020 mg · Polvo para solución para perfusión | Vancomycin | Spain | Marketed | 2016 |
| VANCOMICINA MIP 500 MG POLVO PARA SOLUCION PARA PERFUSION EFG510 mg · Polvo para solución para perfusión | Vancomycin | Spain | Marketed | 2016 |
| Vancomycine MIP 1000 mg, poeder voor oplossing voor infusiePoeder voor oplossing voor infusie | Vancomycin | Netherlands | Authorised | 2014 |
| Vancomycine MIP 500 mg, poeder voor oplossing voor infusiePoeder voor oplossing voor infusie | Vancomycin | Netherlands | Authorised | 2014 |
| CEFOTAXIM MIP 1 g1g · Pulb. pt. sol. inj./perf. | Cefotaxime | Romania | unknown | |
| CLINDAMYCIN-MIP 600 mg600mg · Compr. film. | Clindamycin | Romania | unknown |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 6 | 6 | 0 | CompaniesAll medicines |
| Netherlands | 6 | 6 | 0 | CompaniesAll medicines |
| Romania | 2 | 0 | 2 | CompaniesAll medicines |
Also in the registers of Croatia, Serbia, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.